IPD meta-analysis of 5 trials (790 patients) with RAS wild-type metastatic colorectal cancer: CMS2 and CMS4 had longer PFS and OS than CMS1; in CMS4, anti-EGFR vs anti-VEGF antibodies improved PFS (HR 0.67) and OS (HR 0.49).
Meta-analysisn = 790 patients
Stahler et al. Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer